Search

Your search keyword '"Wedi B"' showing total 11 results
Start Over Author "Wedi B" Topic immunology and allergy
11 results on '"Wedi B"'

1. Peanut���induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry

Author

Maris, Ioana, D��lle���Bierke, Sabine, Renaudin, Jean���Marie, Lange, Lars, Koehli, Alice, Spindler, Thomas, Hourihane, Jonathan, Scherer, Kathrin, Nemat, Katja, Kemen, C., Neust��dter, Irena, Vogelberg, Christian, Reese, Thomas, Yildiz, Ismail, Szepfalusi, Zsolt, Ott, Hagen, Straube, Helen, Papadopoulos, Nikolaos G., H��mmerling, Susanne, Staden, Ute, Polz, Michael, Mustakov, Tihomir, Cichocka���Jarosz, Ewa, Cocco, Renata, Fiocchi, Alessandro Giovanni, Fernandez���Rivas, Montserrat, Worm, Margitta, Gr��nhagen, J, Wittenberg, M, Beyer, K, Henschel, A, K��per, S, M��ser, A, Fuchs, T, Ru��ff, F, Wedi, B, Hansen, G, Buck, T, B��sselberg, J, Dr��gerdt, R, Pfeffer, L, Dickel, H, K��rner���Rettberg, C, Merk, H, Lehmann, S, Bauer, A, Nordwig, A, Zeil, S, Hannapp, C, Wagner, N, Rietschel, E, Hunzelmann, N, Huseynow, I, Treudler, R, Aurich, S, Prenzel, F, Klimek, L, Pfaar, O, Reider, N, Aberer, W, Varga, E, Bogatu, B, Schmid���Grendelmeier, P, Guggenheim, R, Riffelmann, F, Kreft, B, Kinaciyan, K, Hartl, L, Ebner, C, Horak, F, Brehler, R, Witte, J, Buss, M, Hompes, S, Bieber, T, Gernert, S, B��cheler, M, Rabe, U, Brosi, W, Nestoris, S, Hawranek, T, Lang, R, Bruns, R, Pf��hler, C, Eng, P, Schweitzer���Krantz, S, Meller, S, Rebmann, H, Fischer, J, Stichtenoth, G, Thies, S, Gerstlauer, M, Utz, P, Neust��dter, I, Klinge, J, Volkmuth, S, Plank���Habibi, S, Schilling, B, Kleinheinz, A, Br��ckner, A, Sch��kel, K, Manolaraki, I, Kowalski, M, Solarewicz���Madajek, K, Tscheiller, S, Seidenberg, J, Cardona, V, Garcia, B, Bilo, M, Caba��es Higuero, N, Vega Castro, A, Poziomkowska���G��sicka, I, B��sing, S, Virchow, C, Christoff, G, Jappe, U, M��ller, S, Kn��pfel, F, Correard, A���K, Rogala, B, Montoro, A, Brandes, A, Muraro, A, Zimmermann, N, Hernandez, D, Minale, P, Niederwimmer, J, Zahel, B, Dahdah, L, Arasi, S, Reissig, A, Eitelberger, F, Asero, R, Hermann, F, Zeidler, S, Pistauer, S, Gei��ler, M, Ensina, L, Plaza Martin, A, Meister, J, Stieglitz, S, Hamelmann, E, and Network For Online Registration Of Anaphylaxis (NORA)

Subjects
0301 basic medicine, Allergy, medicine.medical_specialty, Adolescent, Arachis, Epinephrine, Immunology, Peanut allergy, Peanut-induced anaphylaxis, paediatrics, 03 medical and health sciences, 0302 clinical medicine, Food allergy, Internal medicine, medicine, anaphylaxis, Humans, Immunology and Allergy, Peanut Hypersensitivity, In patient, Registries, Child, Asthma, food allergy, business.industry, food and beverages, medicine.disease, Comorbidity, 030104 developmental biology, 030228 respiratory system, business, Anaphylaxis, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Background Peanut allergy has a rising prevalence in high-income countries, affecting 0.5%-1.4% of children. This study aimed to better understand peanut anaphylaxis in comparison to anaphylaxis to other food triggers in European children and adolescents. Methods Data was sourced from the European Anaphylaxis Registry via an online questionnaire, after in-depth review of food-induced anaphylaxis cases in a tertiary paediatric allergy centre. Results 3514 cases of food anaphylaxis were reported between July 2007 - March 2018, 56% in patients younger than 18 years. Peanut anaphylaxis was recorded in 459 children and adolescents (85% of all peanut anaphylaxis cases). Previous reactions (42% vs. 38%; p = .001), asthma comorbidity (47% vs. 35%; p < .001), relevant cofactors (29% vs. 22%; p = .004) and biphasic reactions (10% vs. 4%; p = .001) were more commonly reported in peanut anaphylaxis. Most cases were labelled as severe anaphylaxis (Ring&Messmer grade III 65% vs. 56% and grade IV 1.1% vs. 0.9%; p = .001). Self-administration of intramuscular adrenaline was low (17% vs. 15%), professional adrenaline administration was higher in non-peanut food anaphylaxis (34% vs. 26%; p = .003). Hospitalization was higher for peanut anaphylaxis (67% vs. 54%; p = .004). Conclusions The European Anaphylaxis Registry data confirmed peanut as one of the major causes of severe, potentially life-threatening allergic reactions in European children, with some characteristic features e.g., presence of asthma comorbidity and increased rate of biphasic reactions. Usage of intramuscular adrenaline as first-line treatment is low and needs to be improved. The Registry, designed as the largest database on anaphylaxis, allows continuous assessment of this condition.

Published
2021
Full Text
View/download PDF

2. National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II

Author

Larenas-Linnemann, D., Antolín-Amérigo, D., Parisi, C., Nakonechna, A., Luna-Pech, J.A., Wedi, B., Davila, I., Gomez, M., Levin, M., Ortega Martell, J.A., Klimek, L., Rosario, N., Muraro, A.M., Agache, I., Bousquet, J., Sheikh, A., International Societes Council, EAACI, Pfaar, O., Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), and Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)

Subjects
medicine.medical_specialty, Allergen immunotherapy, Editorial independence, Immunology, Alternative medicine, Rigour, sublingual immunotherapy, Likert scale, 03 medical and health sciences, 0302 clinical medicine, subcutaneous immunotherapy, Journal Article, medicine, Immunology and Allergy, Humans, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, AGREE II instrument, ComputingMilieux_MISCELLANEOUS, allergic rhinitis, business.industry, Stakeholder, Guideline, Project team, 3. Good health, 030228 respiratory system, Desensitization, Immunologic, Family medicine, Practice Guidelines as Topic, allergen immunotherapy, business
Abstract

Background Since 1988, numerous allergen immunotherapy guidelines (AIT-GLs) have been developed by national and international organizations to guide physicians in AIT. Even so, AIT is still severely underused. Objective To evaluate AIT-GLs with AGREE-II, developed in 2010 by McMaster University methodologists to comprehensively evaluate GL quality. Methods Allergist, from different continents, knowledgeable in AIT and AGREE-II trained were selected into the project team. The project received methodologists’ guidance. AIT-GLs in any language were sought from 1980 to 2016; AIT-GLs were AGREE II-evaluated by at least 2 team members, independently; discrepancies were resolved in a second round, by team discussion or methodologists’ consulting. Results We found 31 AIT-GLs (15 post-2010), ranging from local consensus reports to international position papers (EAACI, AAAAI-ACAAI, WAO). Pre-2010 GLs scored 1.6-4.6 (23%-67%) and post-2010 GLs scored 2.1-6 (30%-86%), on a 7-point Likert scale. The highest scores went to: German-Austrian-Swiss (6.0), Mexican (5.1), and the AAAAI/ACAAI AIT-GL (4.7). These were also the only 3 GLs that received “yes” of both evaluators to the item: “I would recommend this GL for use.” The domains of “Stakeholder involvement” and “Rigor of Development” only scored 3/7, and “Applicability” scored the lowest. Strikingly, newer GLs only scored clearly better in “Editorial independence” and “Global evaluation.” Conclusions In AIT-GLs, there is still a lot of room for improvement, especially in domains crucial for the dissemination. For some GLs, the “Scientific rigor” domain flawed. When resources are limited, transculturizing a high-quality GL might be preferable over developing a GL from zero. Our study and AGREE-II could help to select the best candidate. Clinical Implications We here evaluate allergen immunotherapy guideline (AIT-GL) quality. Only high-quality AIT-GLs should be consulted for AIT management decisions. In low-resource settings, transculturization of these is preferred over developing low-quality guidelines.

Published
2018
Full Text
View/download PDF

3. Management of hypersensitivity reactions to iodinated contrast media

Author

Brockow, Knut, Christiansen, C., Kanny, G., Clément, O., Barbaud, A., Bircher, A., Dewachter, P., Guéant, J. L., Rodriguez Guéant, R. M., Mouton Faivre, C., Ring, J., Romano, A., Sainte Laudy, J., Demoly, P., Pichler, W. J., Aberer, W., Ballmer Weber, B. K., Bilo, M. B., Birnbaum, J., Blanca, M., Blõmecke, B., Campi, P., De Weck, A., Drouet, M., Dzviga, C., Fernandez, J., Gomez, E., Kapp, A., Kidon, M., Kowalski, M., Laroche, D., Mertès, M., Merk, H., Moneret Vautrin, D. A., Pascual Marcos, C., Rebelo Gomes, E., Rueff, F., Sanz, M. L., Torres, M. J., Vervloet, D., Wedi, B., MARONE, GIANNI, Brockow, Knut, Christiansen, C., Kanny, G., Clément, O., Barbaud, A., Bircher, A., Dewachter, P., Guéant, J. L., Rodriguez Guéant, R. M., Mouton Faivre, C., Ring, J., Romano, A., Sainte Laudy, J., Demoly, P., Pichler, W. J., Aberer, W., Ballmer Weber, B. K., Bilo, M. B., Birnbaum, J., Blanca, M., Blõmecke, B., Campi, P., De Weck, A., Drouet, M., Dzviga, C., Fernandez, J., Gomez, E., Kapp, A., Kidon, M., Kowalski, M., Laroche, D., Marone, Gianni, Mertès, M., Merk, H., Moneret Vautrin, D. A., Pascual Marcos, C., Rebelo Gomes, E., Rueff, F., Sanz, M. L., Torres, M. J., Vervloet, D., and Wedi, B.

Subjects
medicine.medical_specialty, Allergy, Premedication, Immunology, Drug Hypersensitivity, Iodinated contrast media, Skin test, Immediate reaction, Prevalence, Immunology and Allergy, Medicine, In patient, Iodine Compound, business.industry, Contrast media, Risk Factor, ALLERGIC/HYPERSENSITIVITY, Nonimmediate reaction, Diagnostic test, medicine.disease, Dermatology, Surgery, Skin reaction, business, Diagnosi, Human
Abstract

All iodinated contrast media (CM) are known to cause both immediate (≤1 h) and nonimmediate (>1 h) hypersensitivity reactions. Although for most immediate reactions an allergic hypersensitivity cannot be demonstrated, recent studies indicate that the severe immediate reactions may be IgE-mediated, while most of the nonimmediate exanthematous skin reactions, appear to be T-cell mediated. Patients who experience such hypersensitivity reactions are therefore advised to undergo an allergologic evaluation. Several investigators have found skin testing to be useful in confirming a CM allergy, especially in patients with nonimmediate skin eruptions. If a patient with confirmed allergy to a CM needs a new CM exposure, a skin test negative CM should be chosen and premedication may be tried. However, none of these precautional measures is a guarantee against a repeat reaction. More research focusing on pathomechanisms, diagnostic testing and premedication is therefore clearly needed in order to prevent CM-induced hypersensitivity reactions in the future.

Published
2005
Full Text
View/download PDF

4. EAACI/GA2LEN/EDF guideline: management of urticaria

Author

Zuberbier, T, Bindslev Jensen, C, Canonica, Giorgio, Grattan, Ce, Greaves, Mw, Henz, Bm, Kapp, A, Kozel, Mm, Maurer, M, Merk, Hf, Schäfer, T, Simon, D, Vena, Ga, Wedi, B, and Eaaci/ga2len/edf

Subjects
Male, Pathology, medicine.medical_specialty, Urticaria, Immunology, Risk Assessment, Severity of Illness Index, Drug Administration Schedule, Quality of life, Cyclosporin a, Anti-Allergic Agents, Humans, Immunology and Allergy, Medicine, media_common.cataloged_instance, Physical urticaria, European union, Intensive care medicine, Adverse effect, Life Style, Randomized Controlled Trials as Topic, media_common, Dose-Response Relationship, Drug, business.industry, Guideline, medicine.disease, Combined Modality Therapy, Response to treatment, Diet, First line treatment, Treatment Outcome, Histamine H1 Antagonists, Quality of Life, Female, business, Immunosuppressive Agents, Follow-Up Studies
Abstract

This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticara, Urticaria 2004, a joint initiative of the EAACI Dermatology Section and GA2LEN. Urticaria has a profound impact on the quality of life, and effective treatment is therefore required. The recommended first line treatment are nonsedating H1 antihistamines. They have proven to be effective in double-blind controlled studies, but dosages increased up to fourfold over the recommended doses may be necessary. However, for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment, additional or alternative therapies may be required. Immunosuppressive drugs like cyclosporin A and corticosteroids are not recommended for long-term treatment due to unavoidable severe adverse effects. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS).

Published
2006
Full Text
View/download PDF

5. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria

Author

Zuberbier, T, Bindslev Jensen, C, Canonica, Giorgio, Grattan, Ce, Greaves, Mw, Henz, Bm, Kapp, A, Kozel, Mm, Maurer, M, Merk, Hf, Schäfer, T, Simon, D, Vena, Ga, Wedi, B, and Eaaci/ga2len/edf

Subjects
Hypersensitivity, Immediate, Male, Urticaria, Immunology, Allergens, Sensitivity and Specificity, Severity of Illness Index, Europe, Risk Factors, Prevalence, Humans, Immunology and Allergy, Female, Skin Tests
Abstract

This guideline is the result of a consensus reached during a panel discussion at the 2nd International Consensus Meeting on Urticaria, Urticaria 2004, a joint initiative of the European Academy of Allergology and Clinical Immunology Dermatology Section and the European Union (EU)-funded network of excellence, GA2LEN. It covers the definition and classification of urticaria, taking into account the recent progress in identifying causes, eliciting factors and pathomechanisms of this disease. We have outlined useful diagnostic approaches for different subtypes of urticaria. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and was formally approved by the European Union of Medical Specialists (UEMS).

Published
2006
Full Text
View/download PDF

6. The Drug Ambassador Project - The diversity of diagnostic procedures for drug allergy around Europe

Author

Gomes, Eva Rebelo, Pichler, Werner J., Demoly, Pascal, Aberer, Werner, Frew, Anthony J., de Weck, Alain, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birnbaum, J., Blanca, M., Blömecke, B., Brockow, K., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Fernandez, J., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Merk, H., Moneret Vaultrin, A. D., Pascual Marcos, C., Przybilla, B., Ring, J., Romano, A., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Torres, M. J., Vervloet, D., Wedi, B., Wüthrich, B., MARONE, GIANNI, Gomes, Eva Rebelo, Pichler, Werner J., Demoly, Pascal, Aberer, Werner, Frew, Anthony J., de Weck, Alain, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birnbaum, J., Blanca, M., Blömecke, B., Brockow, K., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Fernandez, J., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Moneret Vaultrin, A. D., Pascual Marcos, C., Przybilla, B., Ring, J., Romano, A., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Torres, M. J., Vervloet, D., Wedi, B., and Wüthrich, B.

Subjects
Immunology and Allergy, Standardization, Diagnosi, Drug hypersensitivity
Published
2005

7. Diagnosis of immediate allergic reactions to beta-lactam antibiotics

Author

Torres, Maria J, Blanca, M., Fernandez, J., Romano, A., De Weck, A., Aberer, W., Brockow, K., Pichler, Werner J., Demoly, Pascal, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birmbaum, J., Blömecke, B., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Frew, T., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Merk, H., Moneret Vautrin, A. D., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Ring, J., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Vervloet, D., Wedi, B., Wüthrich, B., MARONE, GIANNI, Torres, Maria J, Blanca, M., Fernandez, J., Romano, A., De Weck, A., Aberer, W., Brockow, K., Pichler, Werner J., Demoly, Pascal, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birmbaum, J., Blömecke, B., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Frew, T., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Moneret Vautrin, A. D., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Ring, J., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Vervloet, D., Wedi, B., and Wüthrich, B.

Subjects
medicine.medical_specialty, Allergy, Clinical immunology, Immunology, beta-Lactams, Beta-lactam, Drug Hypersensitivity, chemistry.chemical_compound, Risk Factors, Clavulanic acid, medicine, Immunology and Allergy, Humans, Drug reaction, Child, Skin Tests, business.industry, medicine.disease, Dermatology, Anti-Bacterial Agents, chemistry, Interest group, business, Algorithms, medicine.drug, Beta lactam antibiotics
Abstract

Allergic reactions to betalactams are the most common cause of adverse drug reactions mediated by specific immunological mechanisms. Reactions may be induced by all betalactams currently available, ranging from benzylpenicillin (BP) to other more recently introduced betalactams, such as aztreonam or the related betalactamase-inhibitor clavulanic acid (Fig. 1) (1–5). Although the production process of betalactams has improved over the years, the number of reactions has not decreased, M. J. Torres, M. Blanca, J. Fernandez, A. Romano, A. de Weck, W. Aberer, K. Brockow, W. J. Pichler, P. Demoly for ENDA, and the EAACI interest group on drug hypersensitivity Allergy Service, Carlos Haya Hospital, Malaga, Spain; Allergy Service, University La Paz, Madrid, Spain; Allergy Section, Dept. Clin. Med., UMH, Elche, Spain; Allergy Service, Catholic University of Rome, Italy; Fondation Gerimmun, Beaumont 18, CH1700, Fribourg, Switzerland; Department of Environmental Dermatology, Graz, Austria; Klinik und Poliklinik f5r Dermatologie und Allergologie, Muenchen, Germany; Clinic for Rheumatology and Clinical Immunology/Allergy, Inselspital, Bern, Switzerland; Maladies Respiratoires-INSERM U454, Hopital Arnaud de Villeneuve, Montpellier, France

Published
2003

8. Nahrungsmittelanaphylaxie : Daten aus dem deutschsprachigen Anaphylaxie- Register 2006 – 2015

Author

Worm, Margitta, Scherer, K., Köhli-Wiesner, A., Ruëff, F., Mahler, V., Lange, L., Treudler, R., Rietschel, E., Szepfalusi, Z., Lang, R., Rabe, U., Reese, T., Schwerk, N., Beyer, K., Hompes, S., Bircher, A., Przybilla, B., Hawranek, T., Hansen, G., Friedrichs, F., Merk, H., Tenbrock, K., Lehmann, S., Gerstlauer, M., Kleine-Tebbe, J., Niggemann, B., Dickel, H., Bücheler, M., Bieber, T., Hanfland, J., Schmitt-Grohe, S., Vlajnic, D., Heckmann, V., Nemat, K., Schäkel, K., Nordwig, A., Schuster, A., Schweitzer-Krantz, S., Hillen, Uwe, Kopp, M., Szliska, C., Klinge, J., Neustädter, I., Fuchs, T., Bruns, R., Marsch, C., Kreft, B., Coors, E., Rebien, W., Wedi, B., Pföhler, C., Rett, M., Henzgen, M., Vöhringer, P., Fölster-Holst, R., Hunzelmann, N., Siebenhaar, G., Nestoris, S., Schirpke, C., Grabbe, J., Stichtenoth, G., Ring, J., Brockow, K., Brehler, R., Yildiz, I., Volkmuth, S., Geißler, M., Polz, M., Riffelmann, F., Thies, S., Lepp, U., Rebmann, H., Spindler, T., Klimek, L., Pfaar, O., Brosi, W., Aberer, W., Varga, E., Reider, N., Huttegger, I., Kinaciyan, T., Hoffmann-Sommergruber, K., Eng, P., Helbling, A., Eigenmann, P., Guggenheim, R., and Schmid-Grendelmeier, P.

Subjects
030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Medizin, Immunology and Allergy
Published
2011

9. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria

Author

Zuberbier, T, Asero, R, Bindslev Jensen, C, Canonica, Giorgio, Church, Mk, Giménez Arnau, A, Grattan, Ce, Kapp, A, Merk, Hf, Rogala, B, Saini, S, Sánchez Borges, M, Schmid Grendelmeier, P, Schünemann, H, Staubach, P, Vena, Ga, Wedi, B, Maurer, M, Dermatology Section of the European Academy of Allergology, Clinical, Immunology, Global, Allergy, Asthma European Network, European Dermatology Forum, and World Allergy Organization

Subjects
Hypersensitivity, Immediate, medicine.medical_specialty, Clinical immunology, Urticaria, Immunology, immune system diseases, parasitic diseases, medicine, Prevalence, Immunology and Allergy, Network of excellence, media_common.cataloged_instance, Humans, Physical urticaria, European union, skin and connective tissue diseases, Child, media_common, Panel discussion, Acute urticaria, business.industry, Infant, Guideline, Allergens, medicine.disease, Dermatology, Family medicine, Child, Preschool, Chronic idiopathic urticaria, business
Abstract

Udgivelsesdato: 2009-Oct This guideline, together with its sister guideline on the management of urticaria [Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Giménez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO Guideline: Management of urticaria. Allergy, 2009; 64:1427-1443] is the result of a consensus reached during a panel discussion at the 3rd International Consensus Meeting on Urticaria, Urticaria 2008, a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO). Urticaria is a frequent disease. The life-time prevalence for any subtype of urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms. In addition, it outlines evidence-based diagnostic approaches for different subtypes of urticaria. The correct management of urticaria, which is of paramount importance for patients, is very complex and is consequently covered in a separate guideline developed during the same consensus meeting. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS).

Published
2009
Full Text
View/download PDF

10. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, Salman, Andaç, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Câmara Agondi, Rosana, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta Fachini Jardim, De Souza Lima, Eduardo Magalhães, Demir, Semra, Dissemond, Joachim, Doğan Günaydın, Sibel, Dorofeeva, Irina, Ensina, Luis Felipe, Ertaş, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Giménez Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zając, Alicja, Katelaris, Constance H., Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M.Sendhil, Lang, Claudia, Larco-Sousa, José Ignacio, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Calderón llosa, Oscar, Makris, Michael, Marsland, Alexander, Medina, Iris V., Meshkova, Raisa, Bastos Palitot, Esther, Parisi, Claudio A.S., Pickert, Julia, Ramon, Germán D., Rodríguez-Gonzalez, Mónica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sánchez Caraballo, Jorge Mario, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, E, Song, Zhiqiang, Soria, Angèle, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B.A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yücel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, Maurer, Marcus, Universitat Autònoma de Barcelona, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A., Cherrez-Ojeda, I., Criado, P. R., Peter, J., Comert-Ozer, E., Abuzakouk, M., Agondi, R. C., Al-Ahmad, M., Altrichter, S., Arnaout, R., Arruda, L. K., Asero, R., Bauer, A., Ben-Shoshan, M., Bernstein, J. A., Bizjak, M., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Busse, P., Campos, R. A., Carne, E., Conlon, N., Criado, R. F., Lima, E. M. D., Demir, S., Dissemond, J., Gunaydin, S. D., Dorofeeva, I., Ensina, L. F., Ertas, R., Ferrucci, S. M., Figueras-Nart, I., Fomina, D., Franken, S. M., Fukunaga, A., Gimenez-Arnau, A. M., Godse, K., Goncalo, M., Gotua, M., Grattan, C., Guillet, C., Inomata, N., Jakob, T., Karakaya, G., Kasperska-Zajac, A., Katelaris, C. H., Kosnik, M., Krasowska, D., Kulthanan, K., Kumaran, M. S., Lang, C., Larco-Sousa, J. I., Lazaridou, E., Leslie, T. A., Lippert, U., Llosa, O. C., Makris, M., Marsland, A., Medina, I. V., Meshkova, R., Palitot, E. B., Parisi, C. A. S., Pickert, J., Ramon, G. D., Rodriguez-Gonzalez, M., Rosario, N., Rudenko, M., Rutkowski, K., Sanchez, J., Schliemann, S., Sekerel, B. E., Serpa, F. S., Serra-Baldrich, E., Song, Z. Q., Soria, A., Staevska, M., Staubach, P., Tagka, A., Takahagi, S., Thomsen, S. F., Treudler, R., Vadasz, Z., Valle, S. O. R., Van Doorn, M. B. A., Vestergaard, C., Wagner, N., Wang, D. H., Wang, L. C., Wedi, B., Xepapadaki, P., Yücel, E., Zalewska-Janowska, A., Zhao, Z. T., Zuberbier, T., Maurer, M., School of Medicine, AII - Infectious diseases, Kocaturk, Emek, Salman, Andac, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Agondi, Rosana Camara, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta F., de Souza Lima, Eduardo M., Demir, Semra, Dissemond, Joachim, Gunaydin, Sibel Dogan, Dorofeeva, Irina, Ensina, Luis Felipe, Ertas, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Gimenez-Arnau, Ana M., Godse, Kiran, Goncalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Lang, Claudia, Ignacio Larco-Sousa, Jose, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Llosa, Oscar Calderon, Makris, Michael, Marsland, Alexander, Medina, Iris, V, Meshkova, Raisa, Palitot, Esther Bastos, Parisi, Claudio A. S., Pickert, Julia, Ramon, German D., Rodriguez-Gonzalez, Monica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sanchez, Jorge, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, Esther, Song, Zhiqiang, Soria, Angele, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B. A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yucel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, and Maurer, Marcus

Subjects
Male, 0301 basic medicine, STRESS, Exacerbation, UCARE, pandemije, Medizin, Omalizumab, SERUM, chronic urticaria, 0302 clinical medicine, Pandemic, Health care, Immunology and Allergy, Chronic Urticaria, treatment, Chronic urticaria, COVID-19, Cyclosporine, SARS-CoV-2, Treatment, zdravljenje, ASSOCIATION, Middle Aged, cyclosporine, omalizumab, pandemic, kronična urtikarija, INFECTIONS, GA(2)LEN, Female, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Coronavirus disease 2019 (COVID-19), Immunology, udc:616-097, pandemics, ciklosporin, Young Adult, 03 medical and health sciences, Patient referral, medicine, Humans, In patient, Patient Reported Outcome Measures, Aged, Internet, business.industry, DEFINITION, Medicine, Allergy, Cross-Sectional Studies, 030104 developmental biology, 030228 respiratory system, Emergency medicine, business
Abstract

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation., Novartis; Sanofi; Menarini Universidad Espiritu Santo; Takeda; Allakos; AstraZeneca; CSL Behring; Genentech; Pharming; GSK; Shire/Takada; BioCryst; ResTORbio; Pearl Therapeutics, CVS Health; Law offices of Levin; Riback; Adelman; Flangel; Vedder Price; Fresenius; Taiho; Kyowa Kirin; Tanabe; Korin; Uriach Pharma; Instituto Carlos III FEDER; Menarini; Amgen; Thermo Fisher; Avene; ALK‐Abello; Bencard/Allergy Therapeutics; Celgene; Allergopharma; Faes Farma; AbbVie; Janssen; Leo Pharma; Lilly; Roche; Genesis; Menlo Therapeutics; UCB; Pfizer; Almirall; Galderma; Allergika; Beiersdorf; Biocryst; Biogen Idec; BMS; Boehringer‐Ingelheim; Eli‐Lilly; Galderma; Hexal; Klosterfrau; LEO‐Pharma; LETI‐Pharma; L´Oreal; Medice; Octapharma; Pflüger; Pharming; Regeneron; Shire; ALK‐Abello; Fraunhofer‐IZI Leipzig; Hautnetz Leipzig/Westsachsen; MSD; HAL‐Allergy; Bencard; Nestle; Nutricia; Bayer Health Care; FAES; Henkel; Allakos; Argenx; Genentech Menarini; Moxie; Aralez; Celldex

Published
2021
Full Text
View/download PDF

11. Reducing the risk of anaphylaxis during anaesthesia: Guidelines for clinical practice

Author

Mertes, P. M., Laxenaire, M. C., Lienhart, A., Aberer, W., Ring, J., Pichler, W. J., Demoly, P., Decroix, G., Dewachter, P., Guéant, J. L., Guilloux, L., Laroche, D., Leynadier, F., Longrois, D., Malinovsky, J. M., Moneret-Vautrin, D. A., Pecquet, C., Pinaud, M., Tréchot, P., Vervloet, D., Wessel, F., Ballmer-Weber, B. K., Barbaud, A., Bilo, B., Birnbaum, J., Bianca, M., Blömecke, B., Brockow, K., Christiansen, C., Weck, A., Dzviga, C., Drouet, M., Eberlein-König, B., Frew, A. T., Fuchs, T., Guéant-Rodriguez, R. M., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, G., Merk, H., Pascual-Marcos, C., Przybilla, B., Rebelo-Gomes, E., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M. L., Tas, E., Romano, A., Torres, M. J., Bettina Wedi, Wüthrich, B., Mertes, Paul Michel, Laxenaire, M. C., Lienhart, A., Aberer, W., Ring, J., Pichler, W. J., Demoly, Pascal, Decroix, G., Dewachter, P., Guéant, J. L., Guilloux, L., Laroche, D., Leynadier, F., Longrois, D., Malinovsky, J. M., Moneret Vautrin, D. A., Pecquet, C., Pinaud, M., Tréchot, P., Vervloet, D., Wessel, F., Ballmer Weber, B. K., Barbaud, A., Bilo, B., Birnbaum, J., Bianca, M., Blömecke, B., Brockow, K., Christiansen, C., De Weck, A., Dzviga, C., Drouet, M., Eberlein König, B., Frew, A. T., Fuchs, T., Guéant Rodriguez, R. M., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M. L., Tas, E., Romano, A., Torres, M. J., Wedi, B., and Wüthrich, B.

Subjects
Anaesthesia, Skin test, Latex, Anaphylaxi, Neuromuscular blocking agent, Hypersensitivity, Tryptase, Immunology and Allergy, IgE, Histamine, Hypnotic

Catalog

Books, media, physical & digital resources
See catalog results